E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Nephropatic cystinosis patients with cystine corneal deposits |
|
E.1.1.1 | Medical condition in easily understood language |
Metabolic disease characterized by abnormal accumulation of the amino acid Cystine in various organs of the body, one of whom is the eyes |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071112 |
E.1.2 | Term | Nephropathic cystinosis |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare efficacy of Cystadrops® versus 0.10% cysteamine hydrochloride eye drops solution in terms of superiority in patients with nephropathic cystinosis. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate safety profile of Cystadrops® in patients with nephropathic cystinosis. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Signed and dated written inform consent form in accordance with local regulations: Having freely given their written informed consent to participate in the study. For patients aged less than 18 years consent will be obtained from the two parents (or legal representatives),
- Diagnosis of cystinosis based on a previous white blood cells cystine concentration > 1.5 nmoles half-cystine per mg protein,
- Presence of corneal crystal deposits attested during a slit-lamp examination within 3 months prior inclusion,
- Ability to comply with their usual eye drops treatment in order to comply with the eyewash regimen of 4 instillations,
- Agreement to move to Ophthalmic Core Laboratory for the assessment visits,
- Likely to be able to participate in all scheduled evaluation and complete all required study procedures,
- In the opinion of the investigator, the patient will be compliant and have a high probability of completing the study. |
|
E.4 | Principal exclusion criteria |
- Patients with uncontrolled hepatic disorder, cardiovascular disease, neurologic disease, or cancer,
- Laboratory tests out of normal range according to the reference laboratory values. Deviations may be accepted if the investigator considers that they are not clinically significant for the conduct of study,
- Patients with history or presence of alcohol abuse or drug addiction,
- Pregnant or breast-feeding women,
- Women of child-bearing potential without effective contraception (oral pill or IUCD),
- Patients likely to be non-compliant to the study procedures or for whom a long-term follow-up seems to be difficult to achieve (In the younger children, the confocal microscopy may not be feasible and therefore will not be excluded from the study but only those patients able to undergo the IVCM procedure should be included in the primary analysis).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Corneal cystine crystal density measured by IVCM (In Vivo Confocal Microscopy), composite score assessed by independent masked reader. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- photophobia (rated by investigator and patient)
- CCCS (corneal cystine crystal score by slit-lamp) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
blinded ophtalmologist who perform an independant and masked reading of the results |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Pharmacy hospital formulation |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 8 |